ADVA
9.7.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that KCOM has deployed its packet edge technology to support the extended rollout of super-fast full fiber broadband. Using the compact ADVA FSP 150 demarcation and aggregation device, the UK-based communication and IT service provider is delivering its gigabit-speed Lightstream services to tens of thousands more business and residential customers in the Yorkshire and Lincolnshire area. The high-density MEF 3.0-certified technology enables KCOM to smoothly transition from 1Gbit/s to 10Gbit/s services in its access network. ADVA’s packet edge solution also ensures that the new infrastructure is ready for 5G mobile services and can easily scale to 200Gbit/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005034/en/
“Our Lightstream service has already had a huge impact on businesses and in homes across this region. Now, ADVA’s technology is empowering us to go further than ever before by creating the UK’s first full-fiber city and delivering super-fast fiber connectivity to previously underserved areas,” said Tim Shaw, managing director, wholesale and networks, KCOM. “By leveraging ADVA’s packet edge device, we’ve been able to smoothly transition to 100Gbit/s capacity in our access network and aggregate lower-speed services. What makes the solution so valuable though are its extra benefits. As well as a small footprint and low power, ADVA’s packet edge technology comes with fully automated service activation. Together with its extended temperature range, this makes it simple to deploy in any environment and on a large scale.”
KCOM’s new network is built on ADVA's 100Gbit/s FSP 150 solution with MEF 3.0 Carrier Ethernet certification. The technology supports 100Gbit/s demarcation and high-scale 10Gbit/s service aggregation in an incredibly compact form factor. KCOM is managing the infrastructure with ADVA’s Ensemble Controller , a unique management system that enables programmatic SDN control. This further improves efficiency by reducing troublesome and time-consuming manual processes while providing KCOM’s maintenance team with total visibility. With its hardware-based timing and full activation testing, the solution also helps KCOM ensure the highest levels of quality and availability. What’s more, its low power consumption and ultra-compact design are key to keeping the cost of KCOM’s Lightstream services low.
“We’re proud to be supporting KCOM in this next phase of its journey. By harnessing our technology and the expertise of our team, KCOM is providing high-speed connectivity to more properties than ever before. It’s also helping to boost the economy in this region of the UK by empowering businesses to expand and seize new revenue opportunities,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our FSP 150 packet edge device features several unique advantages, such as its unique ability to verify the performance of high-bitrate services with line-rate 100Gbit/s pre-activation testing. It really is the ultimate tool for operators who need to scale their networks quickly and affordably to tackle exponential growth in data demand and lay the foundations for 5G.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About KCOM
KCOM is a leading provider of communications and IT services. Its foundations date back to 1904 when Hull’s local authority established its own telephone network and it is the reason Hull is the only city in the UK where BT does not operate. KCOM was owned entirely by Hull City Council until its flotation on the London Stock Exchange in 1999 and in August 2019 it was acquired for £627m by Macquarie European Infrastructure Fund 6, an investment fund managed by Macquarie Infrastructure and Real Assets (MIRA). The company has a long history of innovation. It installed the first all-digital telephone network in Europe and launched the first commercial broadband service in the UK. It also introduced the UK’s first online TV service in 1999, pre-empting today’s streaming and downloading technology by decades. Today KCOM provides broadband and phone services to more than 140,000 consumers and businesses in Hull and East Yorkshire while its national arm provides connectivity and IT services to public and private sector organisations across the UK. www.kcom.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005034/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
